

Pfizer Independent Medical Education RFP

Improving Early Detection and Appropriate Anticoagulant Therapy for Atrial Fibrillation

Competitive Grant Program –Pfizer Internal Review Process



Overview

The purpose of this competitive program is to support education program for healthcare professionals to make evidence-based diagnosis and treatment decisions with the aim of eradicating cardioembolic stroke in patients with atrial fibrillation.



Geographic Scope

Japan



Project Types and Area of Interest

Potential applicants are encouraged to identify and address educational needs, barriers and gaps related to cardioembolic stroke prevention in patients with atrial fibrillation.



Key Milestones

- Application submission deadline: August 8, 2023
- Anticipated decision notification date: **October 1, 2023**
- Anticipated project start date: January 1, 2024



Funding Range and Project Length

- Individual projects requesting up to 5,000,000 JPY will be considered.
- Project execution period: January 1, 2024 - December 31, 2024

Note this RFP is also available in [Japanese](#) for your convenience

I. Eligibility

Geographic Scope:

- Japan

Applicant Eligibility Criteria

- The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. All institutions must have a relevant role and the requesting organization must have a key role in the project.

II. Requirements

Date RFP Issued

- April 5, 2023

Clinical Area

- Atrial fibrillation, Cardioembolic Stroke

General Area of Interest for this RFP:

- Projects that will be considered for Pfizer support will focus on education on early detection of paroxysmal and asymptomatic atrial fibrillation, selection of anticoagulant therapy based on appropriate risk assessment of embolism and bleeding, and adherence to medication.

IMPORTANT: *It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. In addition, it is not also our intent to support guideline development (e.g., clinical treatment guidelines) from the viewpoint of COI.*

Target Audience

- Doctors, nurses, pharmacists, and medical professionals involved in the care of patients with cardiovascular diseases

Expected Approximate Monetary Range of Grant Applications:

- Individual projects requesting up to 5,000,000JPY will be considered.

Key Dates:

- RFP release date: 4/5/2023
- Grant Application due date: 8/8/2023
 - Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
- Anticipated Grant Award Notification Date: 10/1/2023
- Grants will be distributed following a fully executed agreement.
- Anticipated Project Start and End Dates: 1/1/2024 to 12/31/2024

How to Submit:

Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled

- Please go to www.cybergrants.com/pfizer/IndependentMedEd and sign in. First-time users should click “Create your password”.
- Click the “START A NEW INDEPENDENT MEDICAL EDUCATION APPLICATION” button.
- In the application:
 - For the question “What type of request are you submitting?” select Response to a Request for Proposal (RFP)
 - For the question “Are you replying to a Request for Proposal (RFP) as part of the Competitive Grant Program?” select Yes
- Select the following Competitive Grant Program Name: “2023 IM JP: Improving Early Detection and Appropriate Therapy for AF”
- Select the following Primary Area of Interest: “CVM-Anti-coagulation (AFIB, VTE)”
- Requirements for submission:
Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

Questions:

- MEG-J Office, Pfizer Japan Inc.
meg.japan@pfizer.com
- Please include the title of this open call, “Improving Early Detection and Appropriate Anticoagulant Therapy for Atrial Fibrillation” in the subject line of your e-mail.

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.
- Payment will only be made to requesting Institution.

Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

Appendix

General RFP Submission Requirements

Applications will be accepted via the online portal listed in the [How to Submit](#) section. Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Full Proposal please ensure it addresses the following sections:

Goals and Objectives

- Briefly state the overall goal of the project.
- List the objectives you plan to meet with your project, in terms of learning and expected outcomes.

Needs Assessment for the Project

- Include a description of your organization's needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.

Target Audience

- Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

Project Design and Methods

- Describe the planned project, the educational approach, and the way the planned methods address the established need.

Innovation

- Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.

Evaluation and Outcomes

- In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.

Dissemination Plan

- Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.

Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.

Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here

Organization Detail

- Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

Budget Detail

- Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application
- While estimating your budget please keep the following items in mind:
 - Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription).
 - Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer. Please [click here](#) for details.